Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action
Нейрохимия / Neurochemical Journal · 2025 · 42 (3) · 368
DOI: 10.7868/s3034556125030052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Нейрохимия / Neurochemical Journal, 2025. Verfasst von T.A. Gudasheva und 3 weiteren Autor:innen.
Abstract (Originalsprache)
This article is a review of studies on the endogenous neuropeptide cyclo-prolylglycine (CPG), which was discovered in Russia in 1996 and subsequently confirmed by numerous international researchers. Cyclo-Pro-Gly is a prominent representative of the regulatory oligopetide group of gliprolines, the development of which was initiated by Academician I.P. Ashmarin. The article describes the broad spectrum of pharmacological activities of CPG, including nootropic, antihypoxic, neuroprotective, anxiolytic, antidepressant-like, antithrombotic, analgesic, anti-addictive, and antitumor effects. Two possible mechanisms of action for CPG are discussed: regulation of the homeostasis of insulin-like growth factor-1 and modulation of glutamatergic AMPA receptors, followed by the activation of neurotrophin tyrosine kinase receptors.
Zitieren
APA
Gudasheva, T., Koliasnikova, K., Alyaeva, A., & Povarnina, P. (2025). Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action. Нейрохимия / Neurochemical Journal, 42(3), 368. https://doi.org/10.7868/s3034556125030052
Vancouver
Gudasheva T, Koliasnikova K, Alyaeva A, Povarnina P. Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action. Нейрохимия / Neurochemical Journal. 2025;42(3):368. doi:10.7868/s3034556125030052
BibTeX
@article{Gudasheva2025,
author = {Gudasheva, T.A. and Koliasnikova, K.N. and Alyaeva, A.G. and Povarnina, P.Yu.},
title = {Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action},
journal = {Нейрохимия / Neurochemical Journal},
year = {2025},
volume = {42},
number = {3},
pages = {368},
doi = {10.7868/s3034556125030052}
}
EUVIMED